Cargando…

Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts

We have evaluated the effect of an adriamycin conjugate of monoclonal antibody Nd2 (ADM‐Nd2) on the growth rate of SW1990 xenografts grown subcutaneously in athymic nude mice. Intravenous or intraperitoneal administration of radiolabeled Nd2 resulted in a maximum tumor accumulation of approximately...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Yasuyuki, Chung, Yong‐Suk, Sawada, Tetsuji, Inui, Akimasa, Yamashita, Yoshito, Hirayama, Koji, Nakata, Bunzo, Ho, Jenny J. L., Kim, Young S., Sowa, Michio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920632/
https://www.ncbi.nlm.nih.gov/pubmed/8567399
http://dx.doi.org/10.1111/j.1349-7006.1995.tb03023.x
_version_ 1783317866260463616
author Kondo, Yasuyuki
Chung, Yong‐Suk
Sawada, Tetsuji
Inui, Akimasa
Yamashita, Yoshito
Hirayama, Koji
Nakata, Bunzo
Ho, Jenny J. L.
Kim, Young S.
Sowa, Michio
author_facet Kondo, Yasuyuki
Chung, Yong‐Suk
Sawada, Tetsuji
Inui, Akimasa
Yamashita, Yoshito
Hirayama, Koji
Nakata, Bunzo
Ho, Jenny J. L.
Kim, Young S.
Sowa, Michio
author_sort Kondo, Yasuyuki
collection PubMed
description We have evaluated the effect of an adriamycin conjugate of monoclonal antibody Nd2 (ADM‐Nd2) on the growth rate of SW1990 xenografts grown subcutaneously in athymic nude mice. Intravenous or intraperitoneal administration of radiolabeled Nd2 resulted in a maximum tumor accumulation of approximately 45% of the initial dose/g of tumor 3‐7 days after administration. However, administration into the tumor produced retention of 1200%ID/g 1 day after, with 50% of this high value remaining even at 7 days after administration. In contrast, intratumoral administration of a nonspecific immunoglobulin showed a lower initial retention and rapid loss of label. Both intravenously and intratumorally administered ADM‐Nd2 reduced the growth rate of SW1990 xenografts. While a single intravenous administration arrested growth for about two weeks, a single intratumoral injection prevented any increase in tumor size even 45 days after administration. Xenografts treated with ADM‐Nd2 showed degenerative changes at the histological level. Neither Nd2 alone nor Adriamycin alone inhibited growth when administered at the same dose as the conjugate.
format Online
Article
Text
id pubmed-5920632
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59206322018-05-11 Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts Kondo, Yasuyuki Chung, Yong‐Suk Sawada, Tetsuji Inui, Akimasa Yamashita, Yoshito Hirayama, Koji Nakata, Bunzo Ho, Jenny J. L. Kim, Young S. Sowa, Michio Jpn J Cancer Res Article We have evaluated the effect of an adriamycin conjugate of monoclonal antibody Nd2 (ADM‐Nd2) on the growth rate of SW1990 xenografts grown subcutaneously in athymic nude mice. Intravenous or intraperitoneal administration of radiolabeled Nd2 resulted in a maximum tumor accumulation of approximately 45% of the initial dose/g of tumor 3‐7 days after administration. However, administration into the tumor produced retention of 1200%ID/g 1 day after, with 50% of this high value remaining even at 7 days after administration. In contrast, intratumoral administration of a nonspecific immunoglobulin showed a lower initial retention and rapid loss of label. Both intravenously and intratumorally administered ADM‐Nd2 reduced the growth rate of SW1990 xenografts. While a single intravenous administration arrested growth for about two weeks, a single intratumoral injection prevented any increase in tumor size even 45 days after administration. Xenografts treated with ADM‐Nd2 showed degenerative changes at the histological level. Neither Nd2 alone nor Adriamycin alone inhibited growth when administered at the same dose as the conjugate. Blackwell Publishing Ltd 1995-11 /pmc/articles/PMC5920632/ /pubmed/8567399 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03023.x Text en
spellingShingle Article
Kondo, Yasuyuki
Chung, Yong‐Suk
Sawada, Tetsuji
Inui, Akimasa
Yamashita, Yoshito
Hirayama, Koji
Nakata, Bunzo
Ho, Jenny J. L.
Kim, Young S.
Sowa, Michio
Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
title Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
title_full Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
title_fullStr Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
title_full_unstemmed Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
title_short Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
title_sort intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920632/
https://www.ncbi.nlm.nih.gov/pubmed/8567399
http://dx.doi.org/10.1111/j.1349-7006.1995.tb03023.x
work_keys_str_mv AT kondoyasuyuki intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT chungyongsuk intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT sawadatetsuji intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT inuiakimasa intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT yamashitayoshito intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT hirayamakoji intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT nakatabunzo intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT hojennyjl intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT kimyoungs intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts
AT sowamichio intratumoralinjectionofanadriamycinimmunoconjugateagainsthumanpancreaticcancerxenografts